Literature DB >> 16959485

Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma.

F Willeke1, A Assad, P Findeisen, E Schromm, R Grobholz, B von Gerstenbergk, A Mantovani, S Peri, H H Friess, S Post, M von Knebel Doeberitz, M H M Schwarzbach.   

Abstract

A unique feature of human soft tissue liposarcoma is a stable (12;16)(q13;p11) translocation observed mainly in myxoid and roundcell liposarcomas. This translocation results in FUS/CHOP fusion transcripts with a corresponding oncogenic protein. We hypothesised that genes downstream of FUS/CHOP might serve as attractive candidates for novel tumour associated antigens. Among a panel of analysed genes, only pentraxin related gene (PTX3) demonstrated high expression in liposarcomas as compared to normal tissues. The analysis of RNA and protein expression demonstrated concordant results. However, the level of RNA and protein overexpression did not correlate in all cases. Finally, PTX3 expression was not related to presence of a FUS/CHOP fusion transcript within the liposarcoma tissues. PTX3 has been associated with adipocyte differentiation and now, additionally, is characterised by a markedly increased expression in human soft tissue liposarcoma. This finding mandates further research efforts to clarify the exact role of PTX3 in liposarcoma oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959485     DOI: 10.1016/j.ejca.2006.05.035

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

Review 1.  Pathogen recognition by the long pentraxin PTX3.

Authors:  Federica Moalli; Sebastien Jaillon; Antonio Inforzato; Marina Sironi; Barbara Bottazzi; Alberto Mantovani; Cecilia Garlanda
Journal:  J Biomed Biotechnol       Date:  2011-06-02

2.  The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.

Authors:  Hayley J Zullow; Akshay Sankar; Davis R Ingram; Daniel D Samé Guerra; Andrew R D'Avino; Clayton K Collings; Rossana Lazcano; Wei-Lien Wang; Yu Liang; Jun Qi; Alexander J Lazar; Cigall Kadoch
Journal:  Mol Cell       Date:  2022-04-06       Impact factor: 19.328

3.  Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells.

Authors:  Andrea Doni; Giovanna Mantovani; Chiara Porta; Jan Tuckermann; Holger M Reichardt; Anna Kleiman; Marina Sironi; Luca Rubino; Fabio Pasqualini; Manuela Nebuloni; Stefano Signorini; Giuseppe Peri; Antonio Sica; Paolo Beck-Peccoz; Barbara Bottazzi; Alberto Mantovani
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

4.  PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer.

Authors:  Cecilia Garlanda; Barbara Bottazzi; Elena Magrini; Antonio Inforzato; Alberto Mantovani
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 5.  Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3.

Authors:  Alberto Mantovani; Cecilia Garlanda; Andrea Doni; Barbara Bottazzi
Journal:  J Clin Immunol       Date:  2007-09-09       Impact factor: 8.317

6.  Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Med       Date:  2021-04-27       Impact factor: 3.984

Review 7.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

8.  Associations between pentraxin 3 and severity of coronary artery disease.

Authors:  Hua Liu; Shaofeng Guan; Weiyi Fang; Fang Yuan; Min Zhang; Xinkai Qu
Journal:  BMJ Open       Date:  2015-04-08       Impact factor: 2.692

9.  Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.

Authors:  S Kondo; H Ueno; H Hosoi; J Hashimoto; C Morizane; F Koizumi; K Tamura; T Okusaka
Journal:  Br J Cancer       Date:  2013-07-04       Impact factor: 7.640

10.  Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function.

Authors:  Bongkun Choi; Eun-Jin Lee; Da-Hyun Song; Sung-Chul Yoon; Yeon-Ho Chung; Youngsaeng Jang; Sang-Min Kim; Youngsup Song; Sang-Wook Kang; Seung-Yong Yoon; Eun-Ju Chang
Journal:  Oncotarget       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.